Muzolimine

Muzolimine
Systematic (IUPAC) name

5-amino-2-[1-(3,4-dichlorophenyl)ethyl]-4H-pyrazol-3-one
Clinical data
Legal status	Withdrawn
Identifiers
ATC code	C03CD01
PubChem	CID 41386
ChemSpider	37766
UNII	07Z36289ZX^Y
KEGG	D05093^Y
Chemical data
Formula	C₁₁H₁₁Cl₂N₃O
Molecular mass	272.13 g/mol
SMILES CC(C1=CC(=C(C=C1)Cl)Cl)N2C(=O)CC(=N2)N
InChI InChI=1S/C11H11Cl2N3O/c1-6(16-11(17)5-10(14)15-16)7-2-3-8(12)9(13)4-7/h2-4,6H,5H2,1H3,(H2,14,15) Key:RLWRMIYXDPXIEX-UHFFFAOYSA-N
Y (what is this?) (verify)

Muzolimine is a loop diuretic.^[1] It is a pyrazole diuretic which was used for treatment of hypertension but was withdrawn worldwide because of severe neurological side effects.^[2]

References

↑ Wangemann, P.; Braitsch, R.; Greger, R. (1987). "The diuretic effect of muzolimine". Pflugers Archiv : European journal of physiology 410 (6): 674–676. PMID 3449804.
↑ Reyes, A. J.; Leary, W. P. (1993). "Clinicopharmacological reappraisal of the potency of diuretics". Cardiovascular Drugs and Therapy 7: 23–28. doi:10.1007/BF00877955. PMID 8435374.

Antihypertensives: diuretics (C03)

Sulfonamides
(and etacrynic acid)

CA inhibitors (at PT)	Acetazolamide

Loop (Na-K-Cl at AL)	Furosemide^# Bumetanide Etacrynic acid Etozoline Muzolimine Piretanide Tienilic acid Torasemide

Thiazides (Na-Cl at DCT, Calcium-sparing)	Altizide Bendroflumethiazide Chlorothiazide Cyclopenthiazide Cyclothiazide Epithiazide Hydrochlorothiazide^# Hydroflumethiazide Mebutizide Methyclothiazide Polythiazide Trichlormethiazide

Thiazide-likes (primarily DCT)	Quinethazone Clopamide Chlortalidone Mefruside Clofenamide Metolazone Meticrane Xipamide Indapamide Clorexolone Fenquizone

Potassium-sparing (at CD)

ESC blockers	Amiloride^# Triamterene Benzamil

Aldosterone antagonists	Spironolactone^# Eplerenone Potassium canrenoate Canrenone

Osmotic diuretics (PT, DL)

Mannitol^#
Urea

Vasopressin receptor antagonists
(DCT and CD)

tetracyclines: Demeclocycline

Other

ethanol, isopropanol, 2M2B
mercurial diuretic (Mersalyl, Meralluride)
Theobromine
Cicletanine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Index of the circulatory system

Description	Anatomy Arteries head and neck arms chest abdomen legs Veins head and neck arms chest abdomen and pelvis legs Development Cells Physiology proteins

Disease	Congenital Neoplasms and cancer Lymphatic vessels Injury Vasculitis Other Symptoms and signs eponymous

Treatment	Procedures Drugs beta blockers channel blockers diuretics nonsympatholytic vasodilatory antihypertensives peripheral vasodilators renin–angiotensin system sympatholytic antihypertensives vasoprotectives